BLSH enters the week defined by a single jarring move: JP Morgan's Kenneth Worthington slashed his price target from $43 to $26 on June 16 — a 40% reduction — while keeping a Neutral rating on a stock that now trades at $25.96.
The JP Morgan cut is the loudest signal this week, and it lands with real force. The revised $26 target sits essentially at the current share price, implying virtually no upside in Worthington's base case. That contrasts sharply with a consensus mean target of $46.95 — a gap so wide it suggests the Street is bifurcated rather than aligned. Citigroup remains the outlier bull, holding a Buy with a $65 target set back in March, while the rest of the covering analysts have steadily trimmed targets since the start of the year. Rosenblatt downgraded to Neutral in April and has moved its target around in a tight range ever since. The direction of travel on the Street is clearly lower, even if the consensus mean hasn't fully repriced yet. The bear case is well-articulated: BLSH earns transaction fees from crypto trading, volumes have softened, and the pending Equiniti acquisition introduces execution risk with limited financial visibility. Bulls point to digital asset infrastructure as a structural growth story, but that thesis needs volumes to cooperate.
The short book reflects genuine conviction against the stock. Short interest runs at 6.8% of free float — meaningful, and it climbed roughly 17% over the past month before pulling back sharply this week, falling 23% in five sessions to around 10.3 million shares. That pullback in short positioning coincided with the stock's own decline, suggesting some bears took profits into weakness rather than adding. Borrow conditions tell a tighter story than the headline short interest might imply. Availability, at 16.5%, means roughly one share remains available for every six already borrowed — well into constrained territory. Earlier this week, availability dropped to near zero on June 15 before easing back, a reminder of just how quickly borrow can disappear in this name. Cost to borrow has climbed nearly 39% over the past week to just under 2%, its highest level in a month, confirming that demand for the borrow is picking up even as gross short interest fell. The ORTEX short score holds at 77.8 — elevated and consistent across the past two weeks — placing this squarely in the top tier of bearishly positioned names.
Options positioning diverges from the short book in an interesting way. Call demand has been running unusually strong relative to recent norms. The put/call ratio at 0.65 is nearly two standard deviations below its 20-day average of 0.73 — meaning options buyers are leaning toward calls, not puts, at a time when the stock has fallen 27% over the past month and the biggest sell-side name on the ticket just cut its target to current prices. That divergence is worth watching: either options traders are fading the weakness or they are positioning for a bounce ahead of the next earnings print, scheduled for August 13.
The institutional picture adds texture. ARK Investment Management added 1.74 million shares as of May 31, bringing its stake to 4.3% of the company — a meaningful vote of confidence from a manager with a track record of holding through volatility in digital asset names. FMR (Fidelity) also added 1.83 million shares through April 30. On the other side, CEO Thomas Farley sold roughly $3.5 million in stock across multiple tranches in early May at prices between $36 and $45 — well above current levels. The insider net for the 90-day window looks nominally positive only because of two equity award grants totaling 160,000 shares; the cash sales are directionally clear.
The stock's earnings history adds weight to the cautious setup. The May 14 Q1 print was punishing — BLSH fell nearly 15% on the day and lost another 14% over the following five sessions. The next print on August 13 now arrives with the stock having shed 27% in a single month, the JP Morgan target anchored at spot, and borrow availability tight enough to make adding to short positions costly. Whether the call-side options activity reflects genuine optimism or simply hedging against a short squeeze in a name with constrained availability is the central question heading into the summer.
See the live data behind this article on ORTEX.
Open BLSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
